Supplementary Materials (business overview)



Medical Data Vision Co.,Ltd.

(Code: 3902)

May 13, 2024



Contents



2 Medical data held by MDV

3 Company Profile	13
-------------------	----


4 Financial Results • Financial Statements ----- 18

medical.data.vision

About Our Business

business model






Our business journey




Steadily expanding business fields, sales, and scale in line with our corporate vision



Change in sales weighting by service



Data network crucial to data collection, turn data utilization into sales



Our strengths



We possess the largest domestic stock of high-quality medical data in the rapidly growing medical big data market

Business conditions

- Valuable big data (47.08mn patients) being collected from the Japanese medical frontline
- Aiming to raise medical care quality by building bonds of trust with major hospitals
- Alliance with DeNA to create the largest DB in Japan for insurers data (22.56m patients)
- Expect further rapid market growth for the data utilization service

Business model

- A hybrid model rooted in marketing capabilities as well as IT
- A business field with barriers to entry that are not easy to overcome
- Significant growth potential from expansion into data utilization services

Earnings structure

- Main business model has strong profitability
- Data network service mostly a recurring revenue business, but a mixed recurring and nonrecurring business model in data utilization service gives the earnings structure balance

Current business opportunities/challenges and the direction of growth



Raise speed of business development by strengthening alliances

Pursue investment in consumer business to realize our future vision

Data network service

Opportunities

Challenges

Sluggish on-premises services

Slow growth in new services

- Grow sales partners via shift to cloud
- Nationwide medical check system sales
 Room to expand the scope of subsidiary
- Room to expand the scope of subsidiary operations
 - _ ____

- Data utilization service
- Market expansion, promote awareness of the benefits of data utilization
- Promote use outside the pharmaceutical sector
- Acquire largest insurer data stock via alliance with DeNA
- Maintaining and improving the speed of growth
- Hire more data analysis staff and expediting training

New businesses


- Lack of large-scale healthcare DB for citizens
- Growth prospects for consumer healthcare business
- New technologies such as BlockChain, Al
- Establish business model for consumer services
- Accelerate links with SBI Group and others


medical.data.vision


Medical data held by MDV


Medical data held by MDV











10

Copyright © Medical Data Vision Co., Ltd. All Rights Reserved.

test data)


Medical database that has both quality and volume



11

No. of patients in medical database exceeds 47mn (47.08mn at end-Mar 2024)


Age distribution of database roughly matches Japan's population pyramid



Source: Based on the Population Projection for Japan (2017 survey), National Institute of Population and Social Security Research

Data users and example uses







■Example uses

- Post-marketing database studies
- Survey of drug prescription trends (by disease, by treatment department)
- Collection of promotional information, evidence extraction
- Target identification and analysis
- Analysis of disease onset factors
- Safety and efficacy validation, evidence extraction
- Feasibility studies
- · Research-use data
- Expanding drug applications etc.

medical.data.vision

Company Profile

Company Profile (As of the end of March 2024)



Company Name	Medical Data Vision Co.,Ltd.
Established	August 20 , 2003
Head Office	Sumitomo Fudosan Kanda Building 10F, 7 KandaMitoshirocho,Chiyoda-ku,Tokyo
Number of Employees	261 employees(Number of employees in the group)
Capital	JPY 992,661,739
President and C E O	Hiroyuki lwasaki
TSE code / TSE market	3902 / Tokyo Stock Exchange Prime Market (Listed on Mothers market in December 16, 2014)
M a j o r Shareholders (As of the end of December 2023)	SBI Holdings, Inc. (29.13%) MEDIPAL HOLDINGS CORPORATION (8.41%) Hiroyuki Iwasaki (President and CEO) (2.09%) CMIC HOLDINGS Co., Ltd. (1.59%) **Shareholding ratio excluding treasury shares
M a j o r Subsidiaries	Doctorbook Inc. System Be Alpha Co., Ltd. Medical Domain Co., Ltd. AIR BIOS Co., Ltd


Main group companies and business fields



Company	Business
Medical Data Vision	 Development, sale & maintenance of management analysis systems Medical data analysis, surveys, consulting
System Be Alpha	 Development, sale & maintenance of software including health consulting systems Agency sales for electronic medical records, etc.
Doctorbook Doctorbook	Creation & operation of medical info video website
*MDI Medical Domain	 Consultation support system Development, sale & maintenance of various data converters
AIR BIOS	Development of new treatments and medical services

Group strategy: unification and utilization of medical and health data





Services overview



[Data network service]

Product	Overview	Price
MDV Act	'Main story' of the free-function can list indicators required for hospital management analysis. In addition, allows benchmarking against other institutions on various indicators for DPC hospitals, regional integrated community care facilities, and convalescent facilities.	Main story Free
IVID V NCC	'Medical analysis package', a paid function, enables data analysis necessary for acute hospitals and care mix hospitals, such as clinical analysis functions and case retrieval functions.	Medical analysis package Y50,000/mth.
	Analysis of charges/DPC fee gap, patient #s/stay length/resources by disease/condition, and benchmarking with other hospitals	Installation: Y4mn
EVE	Uses benchmarks to identify user hospital's trends/strengths & weaknesses, helps with detailed investigation of treatment policy as core of hospital management	Maintenance: Y50,000/mth.
Madical Cada	Uses standardized format for DPC/elec. receipt data to support hospital management in areas like costing, raising treatment prices	Installation: Y8.2mn
Medical Code	Unlimited user registration promotes smooth internal data sharing, change in awareness/actions to help improve management	Maintenance: Y100,000/mth.

[Data utilization service]

Product	Overview	Price	
MDV analyzer	Online analysis tool allowing clients to easily examine data on patient numbers, prescription lengths/volumes using Japan's largest medical database	Y20mn/yr.	
	Enables multifaceted analysis based on actual medical practice (surgery, testing) as well as disease and drug regimen		
Medical data survey analysis	Provision of tailored reports in line with client's wishes	Avg. Y3.5-4mn per survey	

medical.data.vision

Financial Results • Financial Statements

Sales breakdown by service, sales progress (cumulative)



		FY2	021			FY2	022			FY2	023			FY2	2024	
(Millions of Yen)	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Data network service total sales	552	1,007	1,501	2,061	490	971	1,506	2,100	388	723	1,053	1,462	332			
Non-recurring	68	107	151	252	67	135	168	237	72	133	158	256	48			
Recurring	220	443	665	886	222	443	664	890	230	442	655	875	220			
New Business (Subsidiaries)	262	455	684	922	200	393	673	973	86	146	239	330	63			
Karteco	-	_	-	-	-	-	-	-	_	_	_	_	0			
Data utilization service total sales	877	1,628	2,450	3,610	1,020	1,885	2,821	4,003	1,022	2,007	3,030	4,434	928			
MDV analyzer	114	245	403	578	186	372	549	735	217	443	657	865	225			
Medical data survey analysis ※	762	1,382	2,047	3,032	833	1,512	2,271	3,268	805	1,563	2,373	3,569	702			
Other service total sales	_	_	_	_	_	_	_	_	147	271	402	521	127			

X Owing to the absorption of MDV Trial on 1 January 2023, its sales, previously listed under "New businesses (subsidiaries)", are now included in Medical data survey analysis.

Business indicators



Main business indicators	FY2021	FY2022	FY2023	FY2024 Q1
Net sales (Ymn)	5,672	6,104	6,419	1,388
Net sales growth (%)	23.9	7.6	5.2	-11.0
Operating income (Ymn)	1,594	1,758	1,770	53
Ordinary income (Ymn)	1,592	1,750	1,700	22
Ordinary income margin (%)	28.1	28.7	26.5	1.6
Net income attributable to owners of parent (Ymn)	1,087	870	979	-15
Net income per share (Y)	27.74	22.77	25.63	-0.41
Net assets (Ymn)	4,205	3,606	4,317	4,049
Total assets (Ymn)	5,534	4,897	6,221	5,632
Net assets per share (Y)	106.69	92.04	111.21	104.25
ROA (%)	29.3	34.0	30.6	0.4
ROE (%)	26.3	24.2	25.2	-0.4
Equity-to-assent ratio (%)	75.1	71.8	68.3	70.7
CoGS (Ymn)	1,028	1,074	1,388	342
SG&A (Ymn)	3,049	3,271	3,260	991

^{*}Per-share data adjusted for past stock splits.

Sales breakdown, other indicators, cash flow statement



Sales breakdown (Ymn)	FY2021	FY2022	FY2023	FY2024 Q1
Data network services	2,061	2,100	1,462	332
Data utilization services	3,610	4,003	4,434	928
Other services	_	_	521	127

Other indicators	FY2021	FY2022	FY2023	FY2024 Q1	
No. of hospitals with paid contracts for 'MDV Act'	_	_	638 _※	652 _※	
No. of hospitals using 'EVE'	770	741	718 **	669 ж	
No. of hospitals using 'Medical Code'	250	233	207	204	
No. of patients in MDV large-scale medical database (10,000)	3,849	4,232	4,600	4,708	
No. of patients in insurer database (10,000)	762	1,797	2,102	2,256	

X Includes hospitals that subscribe to and use 'EVE' and 'MDV Act' paid contracts.

Cash flow statement (Ymn)	FY2021	FY2022	FY2023
Cash and cash equivalents at beginning of period	3,177	3,202	2,264
CF from operating activities	1,082	910	1,619
CF from investing activities	-26	-868	-437
CF from financing activities	-1,030	-979	-225
Net increase(decrease) in cash and cash equivalents	25	-937	953
Cash and cash equivalents at end of period	3,202	2,264	3,218

Balance sheet



Balance sheet (Ymn)	End-FY2021	End-FY2022	End-FY2023	FY2024 Q1
Current assets	4,525	3,524	3,524	4,009
Cash and deposits	3,221	2,264	2,264	2,854
Accounts receivable – trade	1,058	967	967	807
Contract assets	_	16	16	14
Raw materials	11	13	13	4
Other	235	265	265	338
Allowance for doubtful accounts	-2	-2	-2	-10
Non-current assets	1,009	1,372	1,372	1,623
Property, plant and equipment	140	137	137	260
Intangible assets	227	259	259	84
Investments and other assets	641	975	975	1,278
Total assets	5,534	4,897	4,897	5,632
Current liabilities	1,243	1,206	1,206	1,473
Accounts payable – trade	97	93	93	123
Income taxes payable	400	95	95	49
Contract liabilities	_	755	755	749
Other	746	262	262	551
Non-current liabilities	85	84	84	109
Asset retirement obligations	72	71	71	96
Other	12	12	12	12
Total liabilities	1,328	1,291	1,291	1,583
Shareholders' equity	4,156	3,535	3,535	4,021
Share capital	992	992	992	992
Capital surplus	1,763	1,838	1,838	1,838
Retained earnings	2,879	3,045	3,045	3,531
Treasury shares	-1,479	-2,341	-2,341	-2,341
Total accumulated other comprehensive income	_	-19	-37	-39
Share acquisition rights		_	3	3
Non-controlling interests	49	90	65	63
Total net assets	4,205	3,606	3,606	4,049
Total liabilities and net assets	5,534	4,897	4,897	5,632

Disclaimer



Contacts

https://en.mdv.co.jp/application/contactus/form.php?TOP-

This document provides information intended solely to help readers' understanding of Medical Data Vision Co., Ltd. (MDV). Thus, MDV has no intention to solicit or encourage investment for securities or financial products mentioned in this document. Also, readers are advised that this document is not a disclosure document or statement of financial performance as required by Japan's Financial Instruments and Exchange Act, Act on Investment Trusts and Investment Corporations, related cabinet orders, cabinet office ordinances or rules, the rules governing companies listed on the Tokyo Stock Exchange, or any other applicable rules. This document contains forward-looking statements, including forecasts of financial position, results of operations, and business-related matters, as well as statements related to the plans and goals of the management of Medical Data Vision Co., Ltd. (MDV). There are a number of known and unknown risks and uncertainties that can cause MDV's actual results or performance to differ materially from any explicit or implicit forecasts contained herein. These forward-looking statements also rest on a number of assumptions with regard to MDV's present and future management strategies, as well as the political and economical environments in which MDV will conduct its future business operations. Although the information contained in this document is the best available at the time of publication, no assurances can be given regarding the accuracy, certainty, validity or fairness of this information. The content of this document can be modified or withdrawn without prior notice.